| 产品描述: | MSC2504877 (M2912) is a potent and orally active tankyrase inhibitor with IC50s of 0.0007, 0.0008, 0.54 µM for TNKS, TNKS2, PARP1, respectively. MSC2504877 increases the expression of AXIN2 and TNKS protein levels and decreases β-catenin levels. MSC2504877 shows anti-tumor activity |
| 靶点: |
PARP1:0.54 μM (IC50);TNKS:0.0007 μM (IC50);TNKS2:0.0008 μM (IC50) |
| 体外研究: |
MSC2504877 (1, 3, 10 µM;24 小时) 增加 APC 突变体 COLO320DM 结直肠肿瘤细胞中 AXIN2 和 TNKS 蛋白水平的表达并降低 β-catenin 蛋白水平。 MSC2504877 (0-100 µM;5 天) 抑制 APC−/− 细胞和 COLO320DM 细胞的存活。 MSC2504877 (1 µM;24 小时) 与 albociclib (HY-50767) (0.03 µM) 联合使用可诱导细胞周期停滞在 G1 期。 Western Blot Analysis Cell Line: APC mutant COLO320DM colorectal tumour cells Concentration: 1, 3, 10 µM Incubation Time: 24 h Result: Increased AXIN2 protein levels and decreased β-catenin levels. |
| 体内研究: |
MSC2504877 (30 mg/kg;口服;一次) 抑制小鼠体内的 TNKS 和 Wnt 信号传导。 MSC2504877 (50 mg/kg+palbociclib (HY-50767) 150mg/kg;口服;一次) 抑制体内 Apc 缺陷细胞的过度增殖。 Animal Model: CB17 SCID mice (APC mutant COLO320DM tumour cell xenografts) Dosage: 30 mg/kg Administration: P.o.; once Result: Elicited an increase in both TNKS and AXIN2 levels in tumours, peaking at 6–10 hours after drug administration and falling 18 hours after. Animal Model: Villin-CreERT2; Apcfl/fl mice Dosage: 50 mg/kg + palbociclib (150 mg/kg) Administration: P.o.; once Result: Suppressed the expression of the archetypal Wnt target gene and stem cell marker Lgr5 and combination drug treatment caused a profound increase in nuclear p21. |
| 参考文献: |
1. Menon M, et al. A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors. Sci Rep. 2019 Jan 17;9(1):201. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.542 ml |
17.709 ml |
35.418 ml |
| 5 mM |
0.708 ml |
3.542 ml |
7.084 ml |
| 10 mM |
0.354 ml |
1.771 ml |
3.542 ml |
| 50 mM |
0.071 ml |
0.354 ml |
0.708 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |